Phase I/II trial of linvoseltamab in R/R MM produces positive pivotal data

Fenghuang “Frank” Zhan invested in inaugural Bart Barlogie Chair for Myeloma Research

Zhan, seated, with Steven Webber (left), dean of the College of Medicine and executive vice chancellor at UAMS, and UAMS chancellor Cam Patterson (right).The University of Arkansas for Medical Sciences College of Medicine invested Fenghuang “Frank” Zhan, a tenured professor of medicine and the research director of the UAMS Winthrop P. Rockefeller Cancer Institute’s Myeloma Center, in the Bart Barlogie Chair for Myeloma Research during a March 13 ceremony.

March 21, 2025

Vol.51 No.11

In Brief

Matteo Paz wins 2025 Regeneron Science Talent Search

Matteo Paz, 18, of Pasadena, CA, won the top award of $250,000 in the 2025 Regeneron Science Talent Search, the U.S.’s longest-running and most distinguished science, technology, engineering, and math competition for high school seniors (The Cancer Letter, March 7, 2025).

March 14, 2025

Vol.51 No.10

Regeneron Science Talent Search finalists press on at a time of uncertainty

Emma Lee Wen knows exactly what science can accomplish.

March 07, 2025

Vol.51 No.09

By Yiqing Wang

Drugs & Targets

FDA accepts review for odronextamab BLA in r/r follicular lymphoma

FDA accepted for review the resubmission of the Regeneron Pharmaceuticals, Inc.’s Biologics License Application for Ordspono (odronextamab) in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy. The target action date for the FDA decision is July 30.

February 28, 2025

Vol.51 No.08

Drugs & Targets

EU, China approve Sarclisa + standard of care for MM

The EU has approved Sarclisa (isatuximab-irfc) in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant, based on data from the IMROZ phase III study.

January 24, 2025

Vol.51 No.03

In Brief

David Chung named director of clinical research at Northwell Health

Northwell Health appointed David J. Chung, a prominent oncologist-investigator, as director of clinical research at the Northwell Health Cancer Institute. In this newly created role, Chung also will serve as system chief of multiple myeloma across Northwell’s cancer centers.

January 17, 2025

Vol.51 No.02

Phase I/II trial of linvoseltamab in R/R MM produces positive pivotal data

YOU MAY BE INTERESTED IN

Fenghuang “Frank” Zhan invested in inaugural Bart Barlogie Chair for Myeloma Research

Matteo Paz wins 2025 Regeneron Science Talent Search

Regeneron Science Talent Search finalists press on at a time of uncertainty

FDA accepts review for odronextamab BLA in r/r follicular lymphoma

EU, China approve Sarclisa + standard of care for MM

David Chung named director of clinical research at Northwell Health

Renew today!

Subscriber content

Never miss an issue!

Login